Clinical Trial: Investigators Testing E-selectin Antagonist/Chemotherapy Combination in R/R AML
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
All articles by Rachel Narozniak, MA
Clinical Trial: Epcoritamab to Be Evaluated in R/R DLBCL
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Clinical Trial: Investigational BTK Inhibitor Undergoes Investigation in CLL, B-Cell Lymphoma
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
Vicineum gets Priority Review for High-Risk, BCG-Unresponsive NMIBC
Vicineum has been awarded a priority review for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Sotorasib Under Review for KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
FDA Greenlights Cosela to Reduce Chemotherapy-Induced Bone Marrow Suppression in ES-SCLC
The Food and Drug Administration (FDA) has approved trilaciclib (Cosela; G1 Therapeutics, Inc.).
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
On the Radar for RCC in 2021: McGregor Discusses Combination Strategies, HIF-2α Inhibition, and Other Key Topics
Bradley McGregor, MD, clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key topics in RCC care in 2021.
First GnRH Receptor Antagonist Enters Advanced Prostate Cancer Treatment Portfolio
Daniel J. George, MD, a lead investigator on the HERO study, discusses the implications of relugolix’s approval for advanced prostate cancer.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...